Psychedelic equity sector gains from today will not hold through mid-September absent a hard clinical/M&A catalyst.

Psychedelic company stocks recently got a boost from general market excitement — not from any specific breakthrough of their own. Without a real concrete milestone like a successful drug trial or a major acquisition, those gains tend to fade. COMPASS Pathways (ticker: CMPS), a leading publicly traded psychedelic company, is being used here as the measuring stick.

Sector-beta rallies driven by sentiment (e.g., Lilly's $3.8B deal) mean-revert without asset-specific catalysts. Using COMPASS Pathways (CMPS) as the named liquid proxy makes this cleanly measurable.